MedPage Today) — Almost 40% of patients with relapsed/refractory lymphomas achieved complete responses (CRs) with a five-drug regimen that targeted different cancer-survival pathways, a preliminary clinical trial showed.
Overall, 54% of patients…
MedPage Today) — Almost 40% of patients with relapsed/refractory lymphomas achieved complete responses (CRs) with a five-drug regimen that targeted different cancer-survival pathways, a preliminary clinical trial showed.
Overall, 54% of patients…
